Literature DB >> 2033268

Guatemalan human onchocerciasis. II. Evidence for IgG3 involvement in acquired immunity to Onchocerca volvulus and identification of possible immune-associated antigens.

A E Boyer1, V C Tsang, M L Eberhard, G Zea-Flores, A Hightower, J B Pilcher, R Zea-Flores, W Zhou, C B Reimer.   

Abstract

Ag-specific isotypic differences in immune response to Onchocerca volvulus Ag were assessed for 778 long term residents of endemic Guatemalan areas by quantitative ELISA with 5-min incubation steps and immunoblot. The study population was separated into five groups based on clinical status: N+F+, N+F-, N-F+, N-F-H+, and N-F-H-, where N = O. volvulus adults (nodule), F = microfiladermia, and H = history of O. volvulus infection. A subset of 44 individuals with high exposure to onchocerciasis from the N-F-H- group were critically evaluated and designated as "putatively immune." IgG1 reactivity to O. volvulus Ag was elevated in the majority of infected persons, but not in putatively immune individuals. Specific IgG3 levels, however, were equally elevated in all groups. The majority of N+F- persons also had elevated IgG1 levels, but they were lower than those found in F+ persons. IgG3 reactivities to a group of antigens at 20 kDa (GP20) were seen in many uninfected persons and some N+F- persons. In contrast, most F+ persons, react to this Ag with IgG1 and not IgG3. A mangabey inoculated with the infectious larval stage of O. volvulus (L3), but showed no signs of infection, began to recognize GP20 at 2 wk postinoculation. Early recognition of GP20 was possibly elicited by the larval stage. Purified nodule Ag from N+F+ individuals contained GP20, however, identical nodule Ag prepared from N+F- individuals did not. These data suggest that GP20 Ag may be common to both uterine microfilaria and the infectious larval stages. The fact that GP20 is predominantly recognized by IgG3 in putatively immune persons and some N+F- persons suggests that this increased IgG3 activity may be important in acquired immunity to onchocerciasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033268

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Evaluation of an OV-16 IgG4 Enzyme-Linked Immunosorbent Assay in Humans and Its Application to Determine the Dynamics of Antibody Responses in a Non-Human Primate Model of Onchocerca volvulus Infection.

Authors:  Vitaliano A Cama; Circe McDonald; Alice Arcury-Quandt; Mark Eberhard; M Harley Jenks; Jared Smith; Sindew M Feleke; Francisca Abanyie; Lakwo Thomson; Ryan E Wiegand; Paul T Cantey
Journal:  Am J Trop Med Hyg       Date:  2018-10       Impact factor: 2.345

2.  The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection.

Authors:  P T Soboslay; S M Geiger; N Weiss; M Banla; C G Lüder; C M Dreweck; E Batchassi; B A Boatin; A Stadler; H Schulz-Key
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

3.  Human onchocerciasis and tetanus vaccination: impact on the postvaccination antitetanus antibody response.

Authors:  P J Cooper; I Espinel; M Wieseman; W Paredes; M Espinel; R H Guderian; T B Nutman
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Differential cytokine and antibody responses to adult and larval stages of Onchocerca volvulus consistent with the development of concomitant immunity.

Authors:  Angus J MacDonald; Prasad S D Turaga; Carolyn Harmon-Brown; Tracy J Tierney; Kristine E Bennett; Maggie C McCarthy; Scott C Simonek; Peter A Enyong; Daniel W Moukatte; Sara Lustigman
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

5.  The novel cuticular collagen Ovcol-1 of Onchocerca volvulus is preferentially recognized by immunoglobulin G3 from putatively immune individuals.

Authors:  G R Stewart; Y Zhu; W Parredes; T I Tree; R Guderian; J E Bradley
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

6.  The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.

Authors:  Fidelis Cho-Ngwa; Jing Liu; Sara Lustigman
Journal:  PLoS Negl Trop Dis       Date:  2010-08-24

7.  Immunological markers indicating the effectiveness of pharmacological treatment in human hydatid disease.

Authors:  R Riganò; E Profumo; S Ioppolo; S Notargiacomo; E Ortona; A Teggi; A Siracusano
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

8.  Tropomyosin implicated in host protective responses to microfilariae in onchocerciasis.

Authors:  R E Jenkins; M J Taylor; N J Gilvary; A E Bianco
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

9.  Human immune responses to infective stage larval-specific chitinase of filarial parasite, Onchocerca volvulus, Ov-CHI-1.

Authors:  Yang Wu; Gillian Egerton; James S McCarthy; Thomas B Nutman; Albert E Bianco
Journal:  Filaria J       Date:  2003-03-14

10.  Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans.

Authors:  Parakkal Jovvian George; Jessica A Hess; Sonia Jain; John B Patton; Tingting Zhan; Nancy Tricoche; Bin Zhan; Maria Elena Bottazzi; Peter J Hotez; David Abraham; Sara Lustigman
Journal:  PLoS Negl Trop Dis       Date:  2019-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.